MindBio Secures Funding for LSD Microdosing Trial in Depression Patients
Vancouver, British Columbia -- July 25, 2022 -- NewsGenie -- MindBio Therapeutics, a Blackhawk Growth Corp. subsidiary, announced that its research collaborators at the University of Auckland in New Zealand have received NZ$1.44 million from the Health Research Council of New Zealand. The funding will support a trial of LSD (Lysergic Acid Diethylamide) microdosing in patients with Major Depressive Disorder.
The grant follows the successful completion of a Phase 1 Clinical Trial involving 80 healthy participants. MindBio is currently collating data from this trial and will release further information as it becomes available.
MindBio is collaborating with the University of Auckland to develop intellectual property and novel microdosing treatments for mental health conditions. These treatments aim to be commercialized for use within the primary health care system.
"We are proud of the work of our scientific collaborators, and the support shown is testament to the calibre of scientists leading the project. We are determined to develop game-changing treatments for mental health conditions," said Frederick Pels, CEO of Blackhawk Growth Corp.
Blackhawk Growth is an investment holding company focused on acquiring and developing high-growth companies in the health, cannabis, and cannabidiol industries in Canada and the United States. Its portfolio includes Sac Pharma, LeichtMind Clinics, and MindBio Therapeutics, among others.